Description

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.

Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!

Faculty

  • Sven Francque (Moderator)
  • Willem Pieter Brouwer (Faculty)
  • Cyrielle Caussy (Faculty)
  • Dimitris Papamargaritis (Faculty)

This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.

Related episodes:

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments